Xcout IntelEdesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Subscribe to see Edesa Biotech, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Edesa Biotech, Inc. at a glance
Edesa Biotech, Inc. is a biotech company headquartered in Markham, Canada. It is publicly listed (EDSA) with a market capitalisation of $47.4M. Xcout tracks 28 named people at Edesa Biotech, Inc., including Pardeep Nijhawan FRCPC (Chief Executive Officer, Company Secretary & Director).
Edesa Biotech, Inc. leadership
- Pardeep Nijhawan FRCPCChief Executive Officer, Company Secretary & Director
- Par NijhawanChief Executive Officer
- Michael J. BrooksPresident
- Michael BrooksPresident
- Peter John WeilerChief Financial Officer
- Peter J. WeilerChief Financial Officer
22 more named people on record for Edesa Biotech, Inc., with roles, board committees and tenure — see the full roster →
Investors
Edesa Biotech, Inc. competitors
A few of Edesa Biotech, Inc.'s closest competitors — see the full list of competitors and alternatives →
Altesa BioSciences is a clinical-stage pharmaceutical company headquartered in College Park, Georgia. The company is dedicated to improving the lives of individuals suffering from chronic lung diseases, including conditions such as COPD and asthma.
Evommune is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, developing new treatments for immune-mediated chronic inflammatory diseases.
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Expedition Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, developing novel oral small molecule therapies for serious inflammatory and respiratory diseases.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Artax Biopharma, Inc. is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company is focused on transforming the treatment of immune system diseases and recently raised $8 million ahead of a Phase 2a clinical trial.
Get Edesa Biotech, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Edesa Biotech, Inc. in Xcout Intel
- 28 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access